Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
Less Infections for the Diabetic Foot  

This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1. For diabetic toe osteomyelitis, the patients will be randomized between a 3 and a 6 week's arm, for soft tissue infections …

antibiotic therapy
diabetic foot infection
osteomyelitis
wound debridement
revascularisation
  • 0 views
  • 19 Feb, 2024
  • 1 location
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a …

venetoclax
interleukin-3
blastic plasmacytoid dendritic cell neoplasm
ejection fraction
oral contraceptives
  • 0 views
  • 19 Feb, 2024
RCT for Electroconvulsive Treatment Followed by Cognitive Control Training

As such, cognitive control training (CCT) holds promise as a non-pharmacological strategy to improve long-term effects of ECT (i.e., increase remission, and reduce depression relapse).

  • 0 views
  • 19 Feb, 2024
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and intravenous immunoglobulins (IVIG) has shown to be effective for refractory pemphigus cases and can potentially induce long-term complete remission and lower risks infectious complications. In this study, investigators will evaluate the efficacy and safety …

enzyme-linked immunosorbent assay
rituximab
immunoglobulins
immunoglobulin
igiv
  • 0 views
  • 19 Feb, 2024
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by …

myelodysplastic syndrome
t-aml
daunorubicin
myeloid leukemia
acute myeloid leukemia with myelodysplasia-related changes
  • 0 views
  • 19 Feb, 2024
Azacitidine Venetoclax and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

This phase II trial investigates how well azacitidine, venetoclax, and trametinib work in treating patients with acute myeloid leukemia or higher-risk myelodysplastic syndrome that has come back (relapsed) or has not responded to treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer …

recurrent acute myeloid leukemia
refractory myelodysplastic syndrome
myelodysplastic syndrome
recurrent chronic myelomonocytic leukemia
HRAS
  • 0 views
  • 19 Feb, 2024
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

  • 0 views
  • 19 Feb, 2024
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.

panic disorder
depo-provera
implanon
nuvaring
major depressive disorder
  • 0 views
  • 19 Feb, 2024
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

rituximab
lymphoma
bortezomib
prednisone
marginal zone lymphoma
  • 0 views
  • 19 Feb, 2024
Acalabrutinib Lenalidomide and Rituximab for the Treatment of CD20 Positive Stage III-IV Grade 1-3a Follicular Lymphoma

This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work …

monoclonal antibodies
rituximab
bone marrow procedure
stage iv grade 1 follicular lymphoma
stage iv grade 2 follicular lymphoma
  • 0 views
  • 19 Feb, 2024